A review of β-amyloid neuroimaging in Alzheimer's disease

Frontiers in Neuroscience

Volumn 8, Issue OCT, 2014, Pages

  Adlard, Paul A ^a   Tran, Bob A ^a   Finkelstein, David I ^a   Desmond, Patricia M ^a,b   Johnston, Leigh A ^a   Bush, Ashley I ^a   Egan, Gary F ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Alzheimer's disease; Biomarkers; CT; Mouse models; MRI; neuroimaging; PET

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; CHOLINE; CREATININE; FLORBETABEN; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; MONOCRYSTALLINE IRON OXIDE NANOPARTICLE; N ACETYLASPARTIC ACID; PRESENILIN; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; AUTOPSY; BIOCHEMISTRY; BRAIN ATROPHY; CEREBROVASCULAR DISEASE; CONTRAST ENHANCEMENT; DIFFUSE LEWY BODY DISEASE; DIFFUSION WEIGHTED IMAGING; DISEASE ASSOCIATION; DISEASE COURSE; EXECUTIVE FUNCTION; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; GRAY MATTER; HIPPOCAMPUS; HUMAN; IN VIVO STUDY; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROTEIN AGGREGATION; PROTEIN FUNCTION; REVIEW; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBDURAL HEMATOMA; SUSCEPTIBILITY WEIGHTED IMAGING; VASCULAR AMYLOIDOSIS;

EID: 84910065300     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2014.00327     Document Type: Review

References (180)

1. Agostinho, P., Cunha, R. A., and Oliveira, C. (2010). Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Curr. Pharm. Des. 16, 2766-2778. doi: 10.2174/138161210793176572
2. Alzheimers, A. (2011). Alzheimer's association report 2011 Alzheimer's disease facts and figures. Alzheimers Dement. 7, 208-244. doi: 10.1016/j.jalz.2011.02.004
3. Amariglio, R. E., Becker, J. A., Carmasin, J., Wadsworth, L. P., Lorius, N., Sullivan, C., et al. (2012). Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia 50, 2880-2886. doi: 10.1016/j.neuropsychologia.2012.08.011
4. Antharam, V., Collingwood, J. F., Bullivant, J. P., Davidson, M. R., Chandra, S., Mikhaylova, A., et al. (2012). High field magnetic resonance microscopy of the human hippocampus in Alzheimer's disease: quantitative imaging and correlation with iron. Neuroimage 59, 1249-1260. doi: 10.1016/j.neuroimage.2011.08.019
5. Arendt, T. (2009). Synaptic degeneration in Alzheimer's disease. Acta Neuropathol. 118, 167-179. doi: 10.1007/s00401-009-0536-x
6. Ashford, J. W., Salehi, A., Furst, A., Bayley, P., Frisoni, G. B., Jack, C. R. Jr., et al. (2011). Imaging the Alzheimer brain. J. Alzheimer's Dis. 26(Suppl. 3), 1-27. doi: 10.3233/JAD-2011-0073
7. Badea, A., Johnson, G. A., and Jankowsky, J. L. (2010). Remote sites of structural atrophy predict later amyloid formation in a mouse model of Alzheimer's disease. Neuroimage 50, 416-427. doi: 10.1016/j.neuroimage.2009.12.070
8. Balducci, C., and Forloni, G. (2011). APP transgenic mice: their use and limitations. Neuromolecular Med. 13, 117-137. doi: 10.1007/s12017-010-8141-7
9. Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., and Jones, E. (2011). Alzheimer's disease. Lancet 377, 1019-1031. doi: 10.1016/S0140-6736(10)61349-9
10. Barba, I., Fernandez-Montesinos, R., Garcia-Dorado, D., and Pozo, D. (2008). Alzheimer's disease beyond the genomic era: nuclear magnetic resonance (NMR) spectroscopy-based metabolomics. J. Cell. Mol. Med. 12, 1477-1485. doi: 10.1111/j.1582-4934.2008.00385.x
11. Bartzokis, G., Tishler, T. A., Lu, P. H., Villablanca, P., Altshuler, L. L., Carter, M., et al. (2007). Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol. Aging. 28, 414-423. doi: 10.1016/j.neurobiolaging.2006.02.005
12. Bartzokis, G., Tishler, T. A., Shin, I. S., Lu, P. H., and Cummings, J. L. (2004). "Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases," in Redox-Active Metals in Neurological Disorders. Annals of the New York Academy of Sciences, Vol. 1012, eds S. M. Levine, J. R. Connor, and H. M. Schipper (New York, NY: The New York Academy of Sciences), 224-236.
13. Beckmann, N. (2011). Probing cerebrovascular alterations in alzheimer's disease using mri: from transgenic models to patients. Curr. Med. Imaging Rev. 7, 51-61. doi: 10.2174/157340511794653531
14. Benveniste, H., Einstein, G., Kim, K. R., Hulette, C., and Johnson, A. (1999). Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. Proc. Natl. Acad. Sci. U.S.A. 96, 14079-14084. doi: 10.1073/pnas.96.24.14079
15. Benveniste, H., Ma, Y., Dhawan, J., Gifford, A., Smith, S. D., Feinstein, I., et al. (2007). "Anatomical and functional phenotyping of mice models of Alzheimer's disease by MR microscopy," in Imaging and the Aging Brain. Annals of the New York Academy of Sciences, eds M. J. DeLeon, D. A. Snider, and H. Federoff (New York, NY: The New York Academy of Sciences), 12-29.
16. Bharadwaj, P. R., Dubey, A. K., Masters, C. L., Martins, R. N., and Macreadie, I. G. (2009). A beta aggregation and possible implications in Alzheimer's disease pathogenesis. J. Cell. Mol. Med. 13, 412-421. doi: 10.1111/j.1582-4934.2009.00609.x
17. Bianchetti, A., and Trabucch, M. (2001). Clinical aspects of Alzheimer's disease. Aging (Milano). 13, 221-230.
18. Blurton-Jones, M., and Laferla, F. M. (2006). Pathways by which Abeta facilitates tau pathology. Curr. Alzheimer Res. 3, 437-448. doi: 10.2174/156720506779025242
19. Bokde, A. L., Ewers, M., and Hampel, H. (2009). Assessing neuronal networks: understanding Alzheimer's disease. Prog. Neurobiol. 89, 125-133. doi: 10.1016/j.pneurobio.2009.06.004
20. Borthakur, A., Gur, T., Wheaton, A. J., Corbo, M., Trojanowski, J. Q., Lee, V. M., et al. (2006). In vivo measurement of plaque burden in a mouse model of Alzheimer's disease. J. Magn. Reson. Imaging 24, 1011-1017. doi: 10.1002/jmri.20751
21. Braakman, N., Matysik, J., van Duinen, S. G., Verbeek, F., Schliebs, R., de Groot, H. J., et al. (2006). Longitudinal assessment of Alzheimer's beta-amyloid plaque development in transgenic mice monitored by in vivo magnetic resonance microimaging. J. Magn. Reson. Imaging 24, 530-536. doi: 10.1002/jmri.20675
22. Braakman, N., van Buchem, M. A., Schliebs, R., de Groot, H. J. M., and Alia, A. (2009). Recent advances in visualizing Alzheimer's plaques by magnetic resonance imaging. Curr. Med. Imaging Rev. 5, 2-9. doi: 10.2174/157340509787354741
23. Brickman, A. M., Small, S. A., and Fleisher, A. (2009). Pinpointing synaptic loss caused by Alzheimer's disease with fMRI. Behav. Neurol. 21, 93-100. doi: 10.1155/2009/246892
24. Brookmeyer, R., Evans, D. A., Hebert, L., Langa, K. M., Heeringa, S. G., Plassman, B. L., et al. (2011). National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimers Dement. 7, 61-73. doi: 10.1016/j.jalz.2010.11.007
25. Bush, A. I. (2008). Drug development based on the metals hypothesis of Alzheimer's disease. J. Alzheimers Dis. 15, 223-240.
26. Casadesus, G., Smith, M. A., Zhu, X., Aliev, G., Cash, A. D., Honda, K., et al. (2004). Alzheimer disease: evidence for a central pathogenic role of iron-mediated reactive oxygen species. J. Alzheimer's Dis. 6, 165-169.
27. Cavedo, E., and Frisoni, G. B. (2011). The dynamic marker hypothesis of Alzheimer's disease and its implications for clinical imaging. Q. J. Nucl. Med. Mol. Imaging 55, 237-249.
28. Chamberlain, R., Reyes, D., Curran, G. L., Marjanska, M., Wengenack, T. M., Poduslo, J. F., et al. (2009). Comparison of amyloid plaque contrast generated by T-2-weighted, T-2(star)-weighted, and susceptibility-weighted imaging methods in transgenic mouse models of alzheimer's disease. Magn. Reson. Med. 61, 1158-1164. doi: 10.1002/mrm.21951
29. Chamberlain, R., Wengenack, T. M., Poduslo, J. F., Garwood, M., and Jack, C. R. (2011). Magnetic resonance imaging of amyloid plaques in transgenic mouse models of Alzheimer's disease. Curr. Med. Imaging Rev. 7, 3-7. doi: 10.2174/157340511794653522
30. Chen, S. Q., Wang, P. J., Ten, G. J., Zhan, W., Li, M. H., and Zang, F. C. (2009). Role of myo-inositol by magnetic resonance spectroscopy in early diagnosis of Alzheimer's disease in APP/PS1 transgenic mice. Dement. Geriatr. Cogn. Disord. 28, 558-566. doi: 10.1159/000261646
31. Chetelat, G., Villemagne, V. L., Pike, K. E., Baron, J. C., Bourgeat, P., Jones, G., et al. (2010). Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain 133, 3349-3358. doi: 10.1093/brain/awq187
32. Coimbra, A., Williams, D. S., and Hostetler, E. D. (2006). The role of MRI and PET/SPECT in Alzheimer's disease. Curr. Top. Med. Chem. 6, 629-647. doi: 10.2174/156802606776743075
33. Connor, D. M., Benveniste, H., Dilmanian, F. A., Kritzer, M. F., Miller, L. M., and Zhong, Z. (2009). Computed tomography of amyloid plaques in a mouse model of Alzheimer's disease using diffraction enhanced imaging. Neuroimage 46, 908-914. doi: 10.1016/j.neuroimage.2009.03.019
34. Crews, L., Rockenstein, E., and Masliah, E. (2010). APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis. Brain Struct. Funct. 214, 111-126. doi: 10.1007/s00429-009-0232-6
35. Dai, Z., Yan, C., Wang, Z., Wang, J., Xia, M., Li, K., et al. (2012). Discriminative analysis of early Alzheimer's disease using multi-modal imaging and multi-level characterization with multi-classifier (M3). Neuroimage 59, 2187-2195. doi: 10.1016/j.neuroimage.2011.10.003
36. Dean, D. C. 3rd, Jerskey, B. A., Chen, K., Protas, H., Thiyyagura, P., Roontiva, A., et al. (2014). Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study. JAMA Neurol. 71, 11-22. doi: 10.1001/jamaneurol.2013.4544
37. Delatour, B., Guegan, M., Volk, A., and Dhenain, M. (2006). In vivo MRI and histological evaluation of brain atrophy in APP/PS1 transgenic mice. Neurobiol. Aging. 27, 835-847. doi: 10.1016/j.neurobiolaging.2005.04.011
38. Dhenain, M., El Tayara, N. E., Wu, T. D., Guegan, M., Volk, A., Quintana, C., et al. (2009). Characterization of in vivo MRI detectable thalamic amyloid plaques from APP/PS1 mice. Neurobiol. Aging 30, 41-53. doi: 10.1016/j.neurobiolaging.2007.05.018
39. Dhenain, M., Privat, N., Duyckaerts, C., and Jacobs, R. E. (2002). Senile plaques do not induce susceptibility effects in T-2*-weighted MR microscopic images. NMR Biomed. 15, 197-203. doi: 10.1002/nbm.760
40. Dickerson, B. C., and Sperling, R. A. (2009). Large-scale functional brain network abnormalities in Alzheimer's disease: insights from functional neuroimaging. Behav. Neurol. 21, 63-75. doi: 10.1155/2009/610392
41. Drago, V., Babiloni, C., Bartres-Faz, D., Caroli, A., Bosch, B., Hensch, T., et al. (2011). Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage. J. Alzheimer's Dis. 26(Suppl. 3), 159-199. doi: 10.3233/JAD-2011-0043
42. Dubois, A., Herard, A. S., Delatour, B., Hantraye, P., Bonvento, G., Dhenain, M., et al. (2010). Detection by voxel-wise statistical analysis of significant changes in regional cerebral glucose uptake in an APP/PS1 transgenic mouse model of Alzheimer's disease. Neuroimage 51, 586-598. doi: 10.1016/j.neuroimage.2010.02.074
43. Elder, G. A., Gama Sosa, M. A., and De Gasperi, R. (2010). Transgenic mouse models of Alzheimer's disease. Mt. Sinai J. Med. 77, 69-81. doi: 10.1002/msj.20159
44. Ellis, K. A., Szoeke, C., Bush, A. I., Darby, D., Graham, P. L., Lautenschlager, N. T., et al. (2014). Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian imaging, biomarkers and lifestyle flagship study of ageing (AIBL). Int. Psychogeriatr. 26, 543-554. doi: 10.1017/S1041610213001956
45. El Tannir El Tayara, N., Delatour, B., Le Cudennec, C., Guegan, M., Volk, A., and Dhenain, M. (2006). Age-related evolution of amyloid burden, iron load, and MR relaxation times in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 22, 199-208. doi: 10.1016/j.nbd.2005.10.013
46. El Tayara Nel, T., Volk, A., Dhenain, M., and Delatour, B. (2007). Transverse relaxation time reflects brain amyloidosis in young APP/PS1 transgenic mice. Magn. Reson. Med. 58, 179-184. doi: 10.1002/mrm.21266
47. Ewers, M., Sperling, R. A., Klunk, W. E., Weiner, M. W., and Hampel, H. (2011). Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci. 34, 430-442. doi: 10.1016/j.tins.2011.05.005
48. Ewers, M., Walsh, C., Trojanowski, J. Q., Shaw, L. M., Petersen, R. C., Jack, C. R. Jr., et al. (2012). Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol. Aging. 33, 1203-1214. doi: 10.1016/j.neurobiolaging.2010.10.019
49. Faber, C., Zahneisen, B., Tippmann, F., Schroeder, A., and Fahrenholz, F. (2007). Gradient-echo and CRAZED imaging for minute detection of Alzheimer plaques in an APPV717I x ADAM10-dn mouse model. Magn. Reson. Med. 57, 696-703. doi: 10.1002/mrm.21201
50. Falangola, M. F., Ardekani, B. A., Lee, S. P., Babb, J. S., Bogart, A., Dyakin, V. V., et al. (2005b). Application of a non-linear image registration algorithm to quantitative analysis of T2 relaxation time in transgenic mouse models of AD pathology. J. Neurosci. Methods. 144, 91-97. doi: 10.1016/j.jneumeth.2004.10.012
51. Falangola, M. F., Dyakin, V. V., Lee, S. P., Bogart, A., Babb, J. S., Duff, K., et al. (2007). Quantitative MRI reveals aging-associated T-2 changes in mouse models of Alzheimer's disease. NMR Biomed. 20, 343-351. doi: 10.1002/nbm.1163
52. Falangola, M. F., Lee, S. P., Nixon, R. A., Duff, K., and Helpern, J. A. (2005a). Histological co-localization of iron in A beta plaques of PS/APP transgenic mice. Neurochem. Res. 30, 201-205. doi: 10.1007/s11064-004-2442-x
53. Faure, A., Verret, L., Bozon, B., El Tannir El Tayara, N., Ly, M., Kober, F., et al. (2011). Impaired neurogenesis, neuronal loss, and brain functional deficits in the APPxPS1-Ki mouse model of Alzheimer's disease. Neurobiol. Aging. 32, 407-418. doi: 10.1016/j.neurobiolaging.2009.03.009
54. Ferreira, L. K., and Busatto, G. F. (2011). Neuroimaging in Alzheimer's disease: current role in clinical practice and potential future applications. Clinics 66(Suppl. 1), 19-24. doi: 10.1590/S1807-59322011001300003
55. Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., et al. (2005). Global prevalence of dementia: a delphi consensus study. Lancet 366, 2112-2117. doi: 10.1016/S0140-6736(05)67889-0
56. Fiala, J. (2007). Mechanisms of amyloid plaque pathogenesis. Acta Neuropathol. 114, 551-571. doi: 10.1007/s00401-007-0284-8
57. Fodero-Tavoletti, M. T., Cappai, R., McLean, C. A., Pike, K. E., Adlard, P. A., Cowie, T., et al. (2009). Amyloid imaging in Alzheimer's disease and other dementias. Brain Imaging Behav. 3, 246-261. doi: 10.1007/s11682-009-9067-2
58. Fodero-Tavoletti, M. T., Villemagne, V. L., Paterson, B. M., White, A. R., Li, Q. X., Camakaris, J., et al. (2010). Bis(thiosemicarbazonato) Cu-64 complexes for positron emission tomography imaging of Alzheimer's disease. J. Alzheimer's Dis. 20, 49-55. doi: 10.3233/JAD-2010-1359
59. Frisoni, G. B., Fox, N. C., Jack, C. R. Jr., Scheltens, P., and Thompson, P. M. (2010). The clinical use of structural MRI in Alzheimer disease. Nat. Rev. Neurol. 6, 67-77. doi: 10.1038/nrneurol.2009.215
60. Giulietti, G., Bozzali, M., Figura, V., Spano, B., Perri, R., Marra, C., et al. (2012). Quantitative magnetization transfer provides information complementary to grey matter atrophy in Alzheimer's disease brains. Neuroimage 59, 1114-1122. doi: 10.1016/j.neuroimage.2011.09.043
61. Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C., and Gage, F. H. (2010). Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918-934. doi: 10.1016/j.cell.2010.02.016
62. Glodzik-Sobanska, L., Rusinek, H., Mosconi, L., Li, Y., Zhan, J., de Santi, S., et al. (2005). The role of quantitative structural imaging in the early diagnosis of Alzheimer's disease. Neuroimaging Clin. N. Am. 15, 803-826. doi: 10.1016/j.nic.2005.09.004
63. Golde, T. E., Dickson, D., and Hutton, M. (2006). Filling the Gaps in the abeta cascade hypothesis of Alzheimer's disease. Curr. Alzheimer Res. 3, 421-430. doi: 10.2174/156720506779025189
64. Götz, J., and Götz, N. N. (2009). Animal models for Alzheimer's disease and frontotemporal dementia: a perspective. ASN Neuro. 1, 251-264. doi: 10.1042/AN20090042
65. Götz, J., Schild, A., Hoerndli, F., and Pennanen, L. (2004). Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. Int. J. Dev. Neurosci. 22, 453-465. doi: 10.1016/j.ijdevneu.2004.07.013
66. Haacke, E. M., Chengb, N. Y. C., House, M. J., Liu, Q., Neelavalli, J., Ogg, R. J., et al. (2005). Imaging iron stores in the brain using magnetic resonance imaging. Magn. Reson. Imaging 23, 1-25. doi: 10.1016/j.mri.2004.10.001
67. Hattori, T., Sato, R., Aoki, S., Yuasa, T., and Mizusawa, H. (2012). Different patterns of fornix damage in idiopathic normal pressure hydrocephalus and Alzheimer disease. AJNR Am. J. Neuroradiol. 33, 274-279. doi: 10.3174/ajnr.A2780
68. Hedden, T., Van Dijk, K. R., Becker, J. A., Mehta, A., Sperling, R. A., Johnson, K. A., et al. (2009). Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J. Neurosci. 29, 12686-12694. doi: 10.1523/JNEUROSCI.3189-09.2009
69. Helpern, J. A., Lee, S. P., Falangola, M. F., Dyakin, V. V., Bogart, A., Ardekani, B., et al. (2004). MRI assessment of neuropathology in a transgenic mouse model of Alzheimer's disease. Magn. Reson. Med. 51, 794-798. doi: 10.1002/mrm.20038
70. Herholz, K., and Ebmeier, K. (2011). Clinical amyloid imaging in Alzheimer's disease. Lancet Neurol. 10, 667-670. doi: 10.1016/S1474-4422(11)70123-5
71. Higuchi, M. (2009). Visualization of brain amyloid and microglial activation in mouse models of Alzheimer's disease. Curr. Alzheimer Res. 6, 137-143. doi: 10.2174/156720509787602906
72. Higuchi, M., Iwata, N., Matsuba, Y., Sato, K., Sasamoto, K., and Saido, T. C. (2005). 19F and 1H MRI detection of amyloid beta plaques in vivo. Nat. Neurosci. 8, 527-533. doi: 10.1038/nn1422
73. Higuchi, M., Maeda, J., Ji, B., Maruyama, M., Okauchi, T., Tokunaga, M., et al. (2010). In vivo visualization of key molecular processes involved in Alzheimer's disease pathogenesis: insights from neuroimaging research in humans and rodent models. Biochim. Biophys. Acta 1802, 373-388. doi: 10.1016/j.bbadis.2010.01.003
74. Honig, L. S., and Mayeux, R. (2001). Natural history of Alzheimer's disease. Aging (Milano). 13, 171-182.
75. House, M. J., St Pierre, T. G., Kowdley, K. V., Montine, T., Connor, J., Beard, J., et al. (2007). Correlation of proton transverse relaxation rates (R2) with iron concentrations in postmortem brain tissue from Alzheimer's disease patients. Magn. Reson. Med. 57, 172-180. doi: 10.1002/mrm.21118
76. House, M. J., St Pierre, T. G., and McLean, C. (2008). 1.4T study of proton magnetic relaxation rates, iron concentrations, and plaque burden in Alzheimer's disease and control postmortem brain tissue. Magn. Reson. Med. 60, 41-52. doi: 10.1002/mrm.21586
77. Hyde, D., de Kleine, R., MacLaurin, S. A., Miller, E., Brooks, D. H., Krucker, T., et al. (2009). Hybrid FMT-CT imaging of amyloid-beta plaques in a murine Alzheimer's disease model. Neuroimage 44, 1304-1311. doi: 10.1016/j.neuroimage.2008.10.038
78. Jack, C. R. Jr., Garwood, M., Wengenack, T. M., Borowski, B., Curran, G. L., Lin, J., et al. (2004). In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn. Reson. Med. 52, 1263-1271. doi: 10.1002/mrm.20266
79. Jack, C. R. Jr., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., et al. (2010). Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9, 119-128. doi: 10.1016/S1474-4422(09)70299-6
80. Jack, C. R. Jr., Lowe, V. J., Senjem, M. L., Weigand, S. D., Kemp, B. J., Shiung, M. M., et al. (2008). 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131(Pt 3), 665-680. doi: 10.1093/brain/awm336
81. Jack, C. R. Jr., Marjanska, M., Wengenack, T. M., Reyes, D. A., Curran, G. L., Lin, J., et al. (2007). Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: a new tool in Alzheimer's disease research. Neuroscientist 13, 38-48. doi: 10.1177/1073858406295610
82. Jack, C. R. Jr., Wengenack, T. M., Reyes, D. A., Garwood, M., Curran, G. L., Borowski, B. J., et al. (2005). In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice. J. Neurosci. 25, 10041-10048. doi: 10.1523/JNEUROSCI.2588-05.2005
83. Kawahara, M. (2010). Neurotoxicity of beta-amyloid protein: oligomerization, channel formation and calcium dyshomeostasis. Curr. Pharm. Des. 16, 2779-2789. doi: 10.2174/138161210793176545
84. Kepe, V., Huang, S. C., Small, G. W., Satyamurthy, N., and Barrio, J. R. (2006). "Visualizing pathology deposits in the living brain of patients with Alzheimer's disease," in Amyloid, Prions, and Other Protein Aggregates, Pt B. Methods in Enzymology, eds I. Kheterpal and R. Wetzel. (San Diego, CA: Elsevier Academic Press Inc), 144-160.
85. Klohs, J., and Rudin, M. (2011). Unveiling molecular events in the brain by noninvasive imaging. Neuroscientist 17, 539-559. doi: 10.1177/1073858410383433
86. Klunk, W. E., Lopresti, B. J., Ikonomovic, M. D., Lefterov, I. M., Koldamova, R. P., Abrahamson, E. E., et al. (2005). Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci. 25, 10598-10606. doi: 10.1523/JNEUROSCI.2990-05.2005
87. Kulkarni, P. V., Roney, C. A., Antich, P. P., Bonte, F. J., Raghu, A. V., and Aminabhavi, T. M. (2010). Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2, 35-47. doi: 10.1002/wnan.59
88. Kuntner, C., Kesner, A. L., Bauer, M., Kremslehner, R., Wanek, T., Mandler, M., et al. (2009). Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. Mol. Imaging Biol. 11, 236-240. doi: 10.1007/s11307-009-0198-z
89. Lee, B. C. P., Mintun, M., Buckner, R. L., and Morris, J. C. (2003). Imaging of Alzheimer's disease. J. Neuroimaging 13, 199-214. doi: 10.1111/j.1552-6569.2003.tb00179.x
90. Lee, C. Y. D., and Landreth, G. E. (2010). The role of microglia in amyloid clearance from the AD brain. J. Neural Transm. 117, 949-960. doi: 10.1007/s00702-010-0433-4
91. Lee, S. P., Falangola, M. F., Nixon, R. A., Duff, K., and Helpern, J. A. (2004). Visualization of beta-amyloid plaques in a transgenic mouse model of Alzheimer's disease using MR microscopy without contrast reagents. Magn. Reson. Med. 52, 538-544. doi: 10.1002/mrm.20196
92. Lehericy, S., Marjanska, M., Mesrob, L., Sarazin, M., and Kinkingnehun, S. (2007). Magnetic resonance imaging of Alzheimer's disease. Eur. Radiol. 17, 347-362. doi: 10.1007/s00330-006-0341-z
93. Leskovjan, A. C., Kretlow, A., Lanzirotti, A., Barrea, R., Vogt, S., and Miller, L. M. (2011). Increased brain iron coincides with early plaque formation in a mouse model of Alzheimer's disease. Neuroimage 55, 32-38. doi: 10.1016/j.neuroimage.2010.11.073
94. Leskovjan, A. C., Lanzirotti, A., and Miller, L. M. (2009). Amyloid plaques in PSAPP mice bind less metal than plaques in human Alzheimer's disease. Neuroimage 47, 1215-1220. doi: 10.1016/j.neuroimage.2009.05.063
95. Li, S. P., He, H. J., Cui, W. G., Gu, B., Li, J., Qi, Z. X., et al. (2010). Detection of a beta plaques by a novel specific MRI probe precursor CR-BSA-(Gd-DTPA)n in APP/PS1 transgenic mice. Anat. Rec. 293, 2136-2143. doi: 10.1002/ar.21209
96. Maeda, J., Ji, B., Irie, T., Tomiyama, T., Maruyama, M., Okauchi, T., et al. (2007). Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J. Neurosci. 27, 10957-10968. doi: 10.1523/JNEUROSCI.0673-07.2007
97. Maeda, J., Zhang, M. R., Okauchi, T., Ji, B., Ono, M., Hattori, S., et al. (2011). In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders. J. Neurosci. 31, 4720-4730. doi: 10.1523/JNEUROSCI.3076-10.2011
98. Maheswaran, S., Barjat, H., Bate, S. T., Aljabar, P., Hill, D. L. G., Tilling, L., et al. (2009). Analysis of serial magnetic resonance images of mouse brains using image registration. Neuroimage 44, 692-700. doi: 10.1016/j.neuroimage.2008.10.016
99. Marjanska, M., Curran, G. L., Wengenack, T. M., Henry, P. G., Bliss, R. L., Poduslo, J. F., et al. (2005). Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. U.S.A. 102, 11906-11910. doi: 10.1073/pnas.0505513102
100. Masters, C. L., Cappai, R., Barnham, K. J., and Villemagne, V. L. (2006). Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. J. Neurochem. 97, 1700-1725. doi: 10.1111/j.1471-4159.2006.03989.x
101. Maynard, C. J., Bush, A. I., Masters, C. L., Cappai, R., and Li, Q. X. (2005). Metals and amyloid-beta in Alzheimer's disease. Int. J. Exp. Pathol. 86, 147-159. doi: 10.1111/j.0959-9673.2005.00434.x
102. McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R. Jr., Kawas, C. H., et al. (2011). The diagnosis of dementia due to Alzheimer's disease: recommendations from the national institute on Aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement. 7, 263-269. doi: 10.1016/j.jalz.2011.03.005
103. Meadowcroft, M. D., Connor, J. R., Smith, M. B., and Yang, Q. X. (2009). MRI and histological analysis of beta-amyloid plaques in both human Alzheimer's disease and APP/PS1 transgenic mice. J. Magn. Reson. Imaging 29, 997-1007. doi: 10.1002/jmri.21731
104. Mi, K., and Johnson, G. V. (2006). The role of tau phosphorylation in the pathogenesis of Alzheimer's disease. Curr. Alzheimer Res. 3, 449-463. doi: 10.2174/156720506779025279
105. Michaelis, T., Abaei, A., Boretius, S., Tammer, R., Frahm, J., Schlumbohm, C., et al. (2009). Intrauterine hyperexposure to dexamethasone of the common marmoset monkey revealed normal cerebral metabolite concentrations in adulthood as assessed by quantitative proton magnetic resonance spectroscopy in vivo. J. Med. Primatol. 38, 213-218. doi: 10.1111/j.1600-0684.2009.00342.x
106. Minati, L., Edginton, T., Bruzzone, M. G., and Giaccone, G. (2009). Current concepts in Alzheimer's disease: a multidisciplinary review. Am. J. Alzheimers Dis. Other Demen. 24, 95-121. doi: 10.1177/1533317508328602
107. Mistur, R., Mosconi, L., De Santi, S., Guzman, M., Li, Y., Tsui, W., et al. (2009). Current challenges for the early detection of Alzheimer's disease: brain imaging and CSF studies. J. Clin. Neurol. 5, 153-166. doi: 10.3988/jcn.2009.5.4.153
108. Mormino, E. C., Brandel, M. G., Madison, C. M., Rabinovici, G. D., Marks, S., Baker, S. L., et al. (2012). Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage 59, 1152-1160. doi: 10.1016/j.neuroimage.2011.07.098
109. Morris, J. C. (2003). Dementia update 2003. Alzheimer Dis. Assoc. Disord. 17, 245-258. doi: 10.1097/00002093-200310000-00010
110. Mosconi, L., Berti, V., Glodzik, L., Pupi, A., De Santi, S., and de Leon, M. J. (2010). pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J. Alzheimers Dis. 20, 843-854. doi: 10.3233/JAD-2010-091504
111. Muller, W. E., Eckert, A., Kurz, C., Eckert, G. P., and Leuner, K. (2010). Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer's disease-therapeutic aspects. Mol. Neurobiol. 41, 159-171. doi: 10.1007/s12035-010-8141-5
112. Murphy, M. P., and LeVine, H. 3rd. (2010). Alzheimer's disease and the amyloid-beta peptide. J. Alzheimer's Dis. 19, 311-323. doi: 10.3233/JAD-2010-1221
113. Muskulus, M., Scheenstra, A. E. H., Braakman, N., Dijkstra, J., Verduyn-Lunel, S., Alia, A., et al. (2009). Prospects for early detection of Alzheimer's disease from serial MR images in transgenic mouse models. Curr. Alzheimer Res. 6, 503-518. doi: 10.2174/156720509790147089
114. Nabuurs, R. J. A., Hegeman, I., Natte, R., van Duinen, S. G., van Buchem, M. A., van der Weerd, L., et al. (2011). High-field MRI of single histological slices using an inductively coupled, self-resonant microcoil: application to ex vivo samples of patients with Alzheimer's disease. NMR Biomed. 24, 351-357. doi: 10.1002/nbm.1598
115. Nakada, T., Matsuzawa, H., Igarashi, H., Fujii, Y., and Kwee, I. L. (2008). In vivo visualization of senile-plaque-like pathology in Alzheimer's disease patients by MR microscopy on a 7T system. J. Neuroimaging 18, 125-129. doi: 10.1111/j.1552-6569.2007.00179.x
116. Nicholson, R. M., Kusne, Y., Nowak, L. A., LaFerla, F. M., Reiman, E. M., and Valla, J. (2010). Regional cerebral glucose uptake in the 3xTG model of Alzheimer's disease highlights common regional vulnerability across AD mouse models. Brain Res. 1347, 179-185. doi: 10.1016/j.brainres.2010.05.084
117. Nikolaus, S., Beu, M., Wirrwar, A., Vosberg, H., Muller, H. W., and Larisch, R. (2004). The contribution of small animal positron emission tomography to the neurosciences-a critical evaluation. Rev. Neurosci. 15, 131-156. doi: 10.1515/REVNEURO.2004.15.2.131
118. Noda-Saita, K., Yoneyama, A., Shitaka, Y., Hirai, Y., Terai, K., Wu, J., et al. (2006). Quantitative analysis of amyloid plaques in a mouse model of Alzheimer's disease by phase-contrast X-ray computed tomography. Neuroscience 138, 1205-1213. doi: 10.1016/j.neuroscience.2005.12.036
119. Oberg, J., Spenger, C., Wang, F. H., Andersson, A., Westman, E., Skoglund, P., et al. (2008). Age related changes in brain metabolites observed by 1H MRS in APP/PS1 mice. Neurobiol. Aging 29, 1423-1433. doi: 10.1016/j.neurobiolaging.2007.03.002
120. Ono, M., Cheng, Y., Kimura, H., Cui, M., Kagawa, S., Nishii, R., et al. (2011). Novel 18F-labeled benzofuran derivatives with improved properties for positron emission tomography (PET) imaging of beta-amyloid plaques in Alzheimer's brains. J. Med. Chem. 54, 2971-2979. doi: 10.1021/jm200057u
121. Palop, J. J., and Mucke, L. (2010). Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 13, 812-818. doi: 10.1038/nn.2583
122. Perl, D. P. (2010). Neuropathology of Alzheimer's disease. Mt. Sinai J. Med. 77, 32-42. doi: 10.1002/msj.20157
123. Philipson, O., Lord, A., Gumucio, A., O'Callaghan, P., Lannfelt, L., and Nilsson, L. N. G. (2010). Animal models of amyloid-beta-related pathologies in Alzheimer's disease. FEBS J. 277, 1389-1409. doi: 10.1111/j.1742-4658.2010.07564.x
124. Poduslo, J. F., Wengenack, T. M., Curran, G. L., Wisniewski, T., Sigurdsson, E. M., Macura, S. I., et al. (2002). Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol. Dis. 11, 315-329. doi: 10.1006/nbdi.2002.0550
125. Rabinovici, G. D., and Jagust, W. J. (2009). Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav. Neurol. 21, 117-128. doi: 10.1155/2009/609839
126. Ramani, A., Jensen, J. H., and Helpern, J. A. (2006). Quantitative MR imaging in Alzheimer disease. Radiology 241, 26-44. doi: 10.1148/radiol.2411050628
127. Reddy, P. H. (2009). Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease. Exp. Neurol. 218, 286-292. doi: 10.1016/j.expneurol.2009.03.042
128. Reiman, E. M., and Caselli, R. J. (1999). Alzheimer's disease. Maturitas 31, 185-200. doi: 10.1016/S0378-5122(98)00110-8
129. Rocchi, A., Pellegrini, S., Siciliano, G., and Murri, L. (2003). Causative and susceptibility genes for Alzheimer's disease: a review. Brain Res. Bull. 61, 1-24. doi: 10.1016/S0361-9230(03)00067-4
130. Rogers, J. T., and Lahiri, D. K. (2004). Metal and inflammatory targets for Alzheimer's disease. Curr. Drug Targets. 5, 535-551. doi: 10.2174/1389450043345272
131. Roney, C. A., Arora, V., Kulkarni, P. V., Antich, P. P., and Bonte, F. J. (2009). Nanoparticulate radiolabelled quinolines detect amyloid plaques in mouse models of Alzheimer's disease. Int. J. Alzheimer's Dis. 2009:481031. doi: 10.4061/2009/481031
132. Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., et al. (2010). Amyloid imaging results from the Australian imaging, biomarkers and lifestyle (AIBL) study of aging. Neurobiol. Aging 31, 1275-1283. doi: 10.1016/j.neurobiolaging.2010.04.007
133. Salek, R. M., Xia, J., Innes, A., Sweatman, B. C., Adalbert, R., Randle, S., et al. (2010). A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease. Neurochem. Int. 56, 937-947. doi: 10.1016/j.neuint.2010.04.001
134. Santos, R. X., Correia, S. C., Wang, X., Perry, G., Smith, M. A., Moreira, P. I., et al. (2010). Alzheimer's disease: diverse aspects of mitochondrial malfunctioning. Int. J. Clin. Exp. Pathol. 3, 570-581.
135. Schrag, M., McAuley, G., Pomakian, J., Jiffry, A., Tung, S., Mueller, C., et al. (2010). Correlation of hypointensities in susceptibility-weighted images to tissue histology in dementia patients with cerebral amyloid angiopathy: a postmortem MRI study. Acta Neuropathol. 119, 291-302. doi: 10.1007/s00401-009-0615-z
136. Scott, C. J. M., Szilagyi, G. M., Chavez, S., Ganda, A., and Black, S. E. (2011). Applications of Chemical Shift Imaging for AD. Curr. Med. Imaging Rev. 7, 88-95. doi: 10.2174/157340511794653513
137. Selkoe, D. J. (2008). Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res. 192, 106-113. doi: 10.1016/j.bbr.2008.02.016
138. Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., et al. (2008). Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842. doi: 10.1038/nm1782
139. Shin, J., Lee, S. Y., Kim, S. J., Kim, S. H., Cho, S. J., and Kim, Y. B. (2010). Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG. Neuroimage 52, 488-496. doi: 10.1016/j.neuroimage.2010.04.013
140. Shin, J., Tsui, W., Li, Y., Lee, S. Y., Kim, S. J., Cho, S. J., et al. (2011). Resting-state glucose metabolism level is associated with the regional pattern of amyloid pathology in Alzheimers disease. Int. J. Alzheimer's Dis. 2011:759780. doi: 10.4061/2011/759780
141. Sigurdsson, E. M., Wadghiri, Y. Z., Mosconi, L., Blind, J. A., Knudsen, E., Asuni, A., et al. (2008). A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiol. Aging 29, 836-847. doi: 10.1016/j.neurobiolaging.2006.12.018
142. Small, G. W., Bookheimer, S. Y., Thompson, P. M., Cole, G. M., Huang, S. C., Kepe, V., et al. (2008). Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol. 7, 161-172. doi: 10.1016/S1474-4422(08)70019-X
143. Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., et al. (2011). Toward defining the preclinical stages of Alzheimer's disease: recommendations from the national institute on Aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement. 7, 280-292. doi: 10.1016/j.jalz.2011.03.003
144. Sperling, R. A., Dickerson, B. C., Pihlajamaki, M., Vannini, P., LaViolette, P. S., Vitolo, O. V., et al. (2010). Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med. 12, 27-43. doi: 10.1007/s12017-009-8109-7
145. Stebbins, G. T., and Murphy, C. M. (2009). Diffusion tensor imaging in Alzheimer's disease and mild cognitive impairment. Behav. Neurol. 21, 39-49. doi: 10.1155/2009/915041
146. Strome, E. M., and Doudet, D. J. (2007). Animal models of neurodegenerative disease: insights from in vivo imaging studies. Mol. Imaging Biol. 9, 186-195. doi: 10.1007/s11307-007-0093-4
147. Sultana, R., Perluigi, M., and Butterfield, D. A. (2009). Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathol. 118, 131-150. doi: 10.1007/s00401-009-0517-0
148. Teipel, S. J., Kaza, E., Hadlich, S., Bauer, A., Bruning, T., Plath, A. S., et al. (2011). Automated Detection of amyloid-beta-related cortical and subcortical signal changes in a transgenic model of Alzheimer's disease using high-field MRI. J. Alzheimers Dis. 23, 221-237. doi: 10.3233/JAD-2010-101035
149. Teng, E., Kepe, V., Frautschy, S. A., Liu, J., Satyamurthy, N., Yang, F., et al. (2011). [F-18]FDDNP microPET imaging correlates with brain Abeta burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-Abeta antibody treatment. Neurobiol. Dis. 43, 565-575. doi: 10.1016/j.nbd.2011.05.003
150. Thiessen, J. D., Glazner, K. A., Nafez, S., Schellenberg, A. E., Buist, R., Martin, M., et al. (2010). Histochemical visualization and diffusion MRI at 7 Tesla in the TgCRND8 transgenic model of Alzheimer's disease. Brain Struct. Funct. 215, 29-36. doi: 10.1007/s00429-010-0271-z
151. Toyama, H., Ye, D., Ichise, M., Liow, J. S., Cai, L., Jacobowitz, D., et al. (2005). PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 32, 593-600. doi: 10.1007/s00259-005-1780-5
152. Valla, J., Chen, K., Berndt, J. D., Gonzalez-Lima, F., Cherry, S. R., Games, D., et al. (2002). Effects of image resolution on autoradiographic measurements of posterior cingulate activity in PDAPP mice: implications for functional brain imaging studies of transgenic mouse models of Alzheimer's Disease. Neuroimage 16, 1-6. doi: 10.1006/nimg.2002.1080
153. Valla, J., Gonzalez-Lima, F., and Reiman, E. M. (2008). FDG autoradiography reveals developmental and pathological effects of mutant amyloid in PDAPP transgenic mice. Int. J. Dev. Neurosci. 26, 253-258. doi: 10.1016/j.ijdevneu.2008.02.003
154. Valla, J., Schneider, L., and Reiman, E. M. (2006). Age- and transgene-related changes in regional cerebral metabolism in PSAPP mice. Brain Res. 1116, 194-200. doi: 10.1016/j.brainres.2006.07.097
155. Vallabhajosula, S. (2011). Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid. Semin. Nucl. Med. 41, 283-299. doi: 10.1053/j.semnuclmed.2011.02.005
156. van Gool, W. A., and Eikelenboom, P. (2000). The two faces of Alzheimer's disease. J. Neurol. 247, 500-505. doi: 10.1007/s004150070147
157. Vanhoutte, G., Dewachter, I., Borghgraef, P., Van Leuven, F., and Van der Linden, A. (2005). Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP V717I transgenic mice, a model for Alzheimer's disease. Magn. Reson. Med. 53, 607-613. doi: 10.1002/mrm.20385
158. Vemuri, P., and Jack, C. R. Jr. (2010). Role of structural MRI in Alzheimer's disease. Alzheimer's Res. Ther. 2, 23. doi: 10.1186/alzrt47
159. Versluis, M. J., Peeters, J. M., van Rooden, S., van der Grond, J., van Buchem, M. A., Webb, A. G., et al. (2010). Origin and reduction of motion and f0 artifacts in high resolution T-2*-weighted magnetic resonance imaging: application in Alzheimer's disease patients. Neuroimage 51, 1082-1088. doi: 10.1016/j.neuroimage.2010.03.048
160. Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., et al. (2013). Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 12, 357-367. doi: 10.1016/S1474-4422(13)70044-9
161. Villemagne, V. L., and Rowe, C. C. (2011). Amyloid imaging. Int. Psychogeriatr. 23(Suppl. 2), S41-S49. doi: 10.1017/S1041610211000895
162. von Kienlin, M., Kunnecke, B., Metzger, F., Steiner, G., Richards, J. G., Ozmen, L., et al. (2005). Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiol. Dis. 18, 32-39. doi: 10.1016/j.nbd.2004.09.005
163. Wadghiri, Y. Z., Sigurdsson, E. M., Sadowski, M., Elliott, J. I., Li, Y., Scholtzova, H., et al. (2003). Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn. Reson. Med. 50, 293-302. doi: 10.1002/mrm.10529
164. Waerzeggers, Y., Monfared, P., Viel, T., Winkeler, A., and Jacobs, A. H. (2010). Mouse models in neurological disorders: applications of non-invasive imaging. Biochim. Biophys. Acta 802, 819-839. doi: 10.1016/j.bbadis.2010.04.009
165. Wengenack, T. M., Jack, C. R. Jr., Garwood, M., and Poduslo, J. F. (2008). MR microimaging of amyloid plaques in Alzheimer's disease transgenic mice. Eur. J. Nucl. Med. Mol. Imaging 35(Suppl. 1), S82-S88. doi: 10.1007/s00259-007-0706-9
166. Wengenack, T. M., Reyes, D. A., Curran, G. L., Borowski, B. J., Lin, J., Preboske, G. M., et al. (2011). Regional differences in MRI detection of amyloid plaques in AD transgenic mouse brain. Neuroimage 54, 113-122. doi: 10.1016/j.neuroimage.2010.08.033
167. Westman, E., Wahlund, L. O., Foy, C., Poppe, M., Cooper, A., Murphy, D., et al. (2011). Magnetic resonance imaging and magnetic resonance spectroscopy for detection of early Alzheimer's disease. J. Alzheimer's Dis. 26(Suppl. 3), 307-319. doi: 10.3233/JAD-2011-0028
168. Wisniewski, T., and Sigurdsson, E. M. (2010). Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochim. Biophys. Acta-Mol. Basis Dis. 1802, 847-859. doi: 10.1016/j.bbadis.2010.05.004
169. Woodhouse, A., Vickers, J. C., Adlard, P. A., and Dickson, T. C. (2009). Dystrophic neurites in TgCRND8 and Tg2576 mice mimic human pathological brain aging. Neurobiol. Aging 30, 864-874. doi: 10.1016/j.neurobiolaging.2007.09.003
170. Wu, W., and Small, S. A. (2006). Imaging the earliest stages of Alzheimer's disease. Curr. Alzheimer Res. 3, 529-539. doi: 10.2174/156720506779025161
171. Xu, W., Zhan, Y., Huang, W., Wang, X., Zhang, S., and Lei, H. (2010). Reduction of hippocampal N-acetyl aspartate level in aged APP(Swe)/PS1(dE9) transgenic mice is associated with degeneration of CA3 pyramidal neurons. J. Neurosci. Res. 88, 3155-3160. doi: 10.1002/jnr.22479
172. Yakushev, I., Gerhard, A., Muller, M. J., Lorscheider, M., Buchholz, H. G., Schermuly, I., et al. (2011a). Relationships between hippocampal microstructure, metabolism, and function in early Alzheimer's disease. Brain Struct. Funct. 216, 219-226. doi: 10.1007/s00429-011-0302-4
173. Yakushev, I., Schreckenberger, M., Muller, M. J., Schermuly, I., Cumming, P., Stoeter, P., et al. (2011b). Functional implications of hippocampal degeneration in early Alzheimer's disease: a combined DTI and PET study. Eur. J. Nucl. Med. Mol. Imaging 38, 2219-2227. doi: 10.1007/s00259-011-1882-1
174. Yanagisawa, D., Amatsubo, T., Morikawa, S., Taguchi, H., Urushitani, M., Shirai, N., et al. (2011). In vivo detection of amyloid beta deposition using (1)F magnetic resonance imaging with a (1)F-containing curcumin derivative in a mouse model of Alzheimer's disease. Neuroscience 184, 120-127. doi: 10.1016/j.neuroscience.2011.03.071
175. Yang, J., Wadghiri, Y. Z., Hoang, D. M., Tsui, W., Sun, Y. J., Chung, E., et al. (2011). Detection of amyloid plaques targeted by USPIO-A beta 1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging. Neuroimage 55, 1600-1609. doi: 10.1016/j.neuroimage.2011.01.023
176. Ye, L., Morgenstern, J. L., Lamb, J. R., and Lockhart, A. (2006). Characterisation of the binding of amyloid imaging tracers to rodent Abeta fibrils and rodent-human Abeta co-polymers. Biochem. Biophys. Res. Commun. 347, 669-677. doi: 10.1016/j.bbrc.2006.06.126
177. Yousefi, B. H., Manook, A., Drzezga, A., von Reutern, B., Schwaiger, M., Wester, H. J., et al. (2011). Synthesis and evaluation of 11C-labeled imidazo[2,1-b]benzothiazoles (IBTs) as PET tracers for imaging beta-amyloid plaques in Alzheimer's disease. J. Med. Chem. 54, 949-956. doi: 10.1021/jm101129a
178. Zahs, K. R., and Ashe, K. H. (2010). "Too much good news" - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends Neurosci. 33, 381-389. doi: 10.1016/j.tins.2010.05.004
179. Zetzsche, T., Rujescu, D., Hardy, J., and Hampel, H. (2010). Advances and perspectives from genetic research: development of biological markers in Alzheimer's disease. Expert Rev. Mol. Diagn. 10, 667-690. doi: 10.1586/erm.10.48
180. Zhang, J., Yarowsky, P., Gordon, M. N., Di Carlo, G., Munireddy, S., van Zijl, P. C., et al. (2004). Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging. Magn. Reson. Med. 51, 452-457. doi: 10.1002/mrm.10730